Home › annual
 

Keywords :   


Tag: annual

Notice to attend the annual general Meeting in Com Hem Holding AB

2015-04-20 21:36:28| Appliances - Topix.net

The shareholders of Com Hem Holding AB , company reg. no. 556858-6613, are hereby invited to attend the annual general meeting to be held on Thursday, 21 May 2015, at 16.00 at Lundqvist & Lindqvist Konferens, Klarabergsviadukten 90 in Stockholm.

Tags: general notice meeting annual

 

MRI Interventions to Exhibit Its ClearPoint Navigation Platform for Neurosurgery at AANS 2015 Annual Meeting

2015-04-20 12:31:14| Industrial Newsroom - All News for Today

IRVINE, Calif.  MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint neuro navigation platform will be on exhibit at the 2015 Annual Meeting of the American Association of Neurological Surgeons (AANS) May 4-6, 2015, in Washington, D.C. Conference attendees are invited to visit the MRI...

Tags: navigation meeting annual platform

 
 

Bactiguard Holding AB (publ): Bactiguarda s Annual Report 2014

2015-04-20 09:11:29| Appliances - Topix.net

The annual report is available in both a Swedish and English online version and as a downloadable PDF document. A printed version of the report will be available from 6 May and can be ordered at info@bactiguard.se .

Tags: report annual holding publ

 

Early Findings with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

2015-04-19 18:45:00| Merck.com - Product News

Dateline City: PHILADELPHIA KEYTRUDA Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer First Findings from KEYNOTE-028, Mercks Innovative Basket Trial in 20 Cancers PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 28 percent with KEYTRUDA in patients with tumors that expressed PD-L1. Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced early presented meeting

 

Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine

2015-04-19 14:30:00| Merck.com - Product News

Dateline City: PHILADELPHIA Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in nave and previously-treated patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of advanced journal published

 

Sites : [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] [304] [305] [306] [307] [308] [309] [310] [311] next »